{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '18', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.11', 'Compliance (Medication Adherence)', '120', '9.12', 'Extent of Exposure', '120', '10', 'SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '121', '10.1', 'Appendix 1: Regulatory, Ethical, and Study Oversight Considerations', '121', '10.1.1', 'Code of Conduct for Clinical Trials', '121', '10.1.2', 'Financial Disclosure', '123', '10.1.3', 'Data Protection', '123', '10.1.3.1', 'Confidentiality of Data', '124', '10.1.3.2', 'Confidentiality of Participant Records', '124', '10.1.3.3', 'Confidentiality of IRB/IEC Information', '124', '10.1.4', 'Committees Structure', '124', '10.1.4.1', 'Steering Committee', '124', '10.1.4.2', 'Executive Oversight Committee', '125', '10.1.4.3', 'External Data Monitoring Committee', '125', '10.1.5', 'Publication Policy', '125', '10.1.6', 'Compliance with Study Registration and Results Posting Requirements 126', '10.1.7', 'Compliance with Law, Audit, and Debarment', '126', '10.1.8', 'Data Quality Assurance', '127', '10.1.9', 'Source Documents', '128', '10.1.10', 'Study and Site Closure', '128', '10.2', 'Appendix 2: Clinical Laboratory Tests', '129', '10.3', 'Appendix 3: Adverse Events: Definitions and Procedures for Recording,', 'Evaluating, Follow-up, and Reporting', '131', '10.3.1', 'Definition of AE', '131', '10.3.2', 'Definition of SAE', '132', '10.3.3', 'Additional Events Reported in the Same Manner as SAE', '133', '10.3.4', 'Recording AE and SAE', '133', '10.3.5', 'Reporting of AEs, SAEs, and Other Reportable Safety Events to the', 'Sponsor', '137', '10.4', 'Appendix 4: Device Events, Adverse Device Events, and Medical Device', 'Incidents: Definitions, Collection, and Documentation', '139', '10.5', 'Appendix 5: Contraceptive Guidance and Pregnancy Testing', '140', '10.5.1', 'Definitions', '140', '10.5.2', 'Contraception Requirements', '141', '10.5.3', 'Pregnancy Testing', '141', '10.6', 'Appendix 6: Description of the iRECIST Process for Assessment of', 'Disease Progression', '143', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '19', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.7 Appendix 7: Country-specific Requirements', '147', '10.7.1', 'Japan-specific Requirements', '147', '10.7.2', 'France-specific Requirements', '147', '10.7.3', 'Canada-specific Requirements', '147', '10.8', 'Appendix 8: Abbreviations', '148', '11 REFERENCES', '152', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}